Biopol Chemicals' (NSE:BIOPOL) Promising Earnings May Rest On Soft Foundations

Despite posting some strong earnings, the market for Biopol Chemicals Limited's (NSE:BIOPOL) stock hasn't moved much. Our analysis suggests that this might be because shareholders have noticed some concerning underlying factors.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

Examining Cashflow Against Biopol Chemicals' Earnings

As finance nerds would already know, the accrual ratio from cashflow is a key measure for assessing how well a company's free cash flow (FCF) matches its profit. In plain english, this ratio subtracts FCF from net profit, and divides that number by the company's average operating assets over that period. This ratio tells us how much of a company's profit is not backed by free cashflow.

Therefore, it's actually considered a good thing when a company has a negative accrual ratio, but a bad thing if its accrual ratio is positive. That is not intended to imply we should worry about a positive accrual ratio, but it's worth noting where the accrual ratio is rather high. Notably, there is some academic evidence that suggests that a high accrual ratio is a bad sign for near-term profits, generally speaking.

Biopol Chemicals has an accrual ratio of 0.74 for the year to September 2026. As a general rule, that bodes poorly for future profitability. To wit, the company did not generate one whit of free cashflow in that time. Even though it reported a profit of ₹113.5m, a look at free cash flow indicates it actually burnt through ₹303m in the last year. Coming off the back of negative free cash flow last year, we imagine some shareholders might wonder if its cash burn of ₹303m, this year, indicates high risk.

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Biopol Chemicals.

Our Take On Biopol Chemicals' Profit Performance

As we have made quite clear, we're a bit worried that Biopol Chemicals didn't back up the last year's profit with free cashflow. For this reason, we think that Biopol Chemicals' statutory profits may be a bad guide to its underlying earnings power, and might give investors an overly positive impression of the company. But at least holders can take some solace from the 43% EPS growth in the last year. The goal of this article has been to assess how well we can rely on the statutory earnings to reflect the company's potential, but there is plenty more to consider. So while earnings quality is important, it's equally important to consider the risks facing Biopol Chemicals at this point in time. At Simply Wall St, we found 3 warning signs for Biopol Chemicals and we think they deserve your attention.

This note has only looked at a single factor that sheds light on the nature of Biopol Chemicals' profit. But there is always more to discover if you are capable of focussing your mind on minutiae. Some people consider a high return on equity to be a good sign of a quality business. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks with significant insider holdings to be useful.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.